Comey, Letitia James Charges Dismissed | Bloomberg Businessweek Daily 11/24/2025

Target is facing significant challenges as it reported declining sales and profits, prompting concerns about its future under incoming CEO Michael Fiddelke, who has been with the company for 22 years. The retailer's culture of high self-regard may have contributed to a lack of urgency in addressing these issues.

The cost of protecting Oracle's debt against default has surged to a multi-year high, with five-year credit default swaps rising to approximately 1.19 percentage points annually, reflecting heightened investor concerns over the company's substantial debt incurred to finance artificial intelligence investments. This marks the highest level since October 2022.

Novo Nordisk's trials of its diabetes and weight loss drug, Ozempic, have failed to demonstrate any positive effects on cognition or functioning in individuals with mild cognitive impairment or dementia, marking a significant setback for the company's ambitions in treating Alzheimer's disease.

U.S. stocks experienced a notable increase as investors reacted positively to expectations of potential interest rate cuts, driven by comments from New York Fed President John Williams regarding a softening labor market. This optimism was reflected in the closing bell coverage by Bloomberg, featuring insights from hosts Scarlet Fu, Carol Massar, and Tim Stenovec.

Novo Nordisk's shares plummeted after the company announced that its Ozempic pill failed to slow the progression of Alzheimer's disease in two late-stage studies. This disappointing outcome has raised concerns about the drug's efficacy and the company's future in the Alzheimer's treatment market.

Novo Nordisk's shares have dropped significantly following the failure of its Ozempic pill in clinical trials aimed at treating Alzheimer's disease, marking yet another setback for the pharmaceutical company. The trials did not show any positive effects on cognition or the progression of the disease, leading to a decline in investor confidence.

Novo Nordisk's stock has been downgraded by HSBC following the failure of its Ozempic medication to demonstrate efficacy in slowing the progression of Alzheimer's disease in clinical trials. This disappointing outcome has led to a significant decline in the company's share value, reflecting investor concerns about its future prospects.

Novo Nordisk's Ozempic pill has failed to demonstrate efficacy in slowing the progression of Alzheimer's disease in two clinical trials, leading to a significant decline in the company's stock value. This disappointing outcome was reported by Naomi Kresge on Bloomberg Television.